| NCT ID | NCT05529264 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 175 participants |
| Start Date | 2023-01-17 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 175 participants in total. It began in 2023-01-17 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will enroll patients with epilepsy who are being evaluated for epilepsy surgery and have electrodes implanted in the brain and/or have electrodes on the scalp. Additionally, this study will recruit normal and online controls (participants who do not have epilepsy). Participants will be asked to participate in 1 to 2 (30-90 minutes) daily sessions designed to test aspects of human cognition such as memory, speech, language, feeling, movement, attention, sound perception, and emotions. Generally, this will involve working on a computer, looking at pictures or watching videos, and answering questions. Additionally, participants may be asked to be hooked up to additional equipment such as eye tracker, electrical stimulator, heart rate monitor, sweat monitor or other non-invasive equipment. The overall aim of this study is to use human intracranial electrophysiology (the recording of the electrical activity of the human brain) to study localization and function of the human brain.
Eligibility Criteria
Patients with Intracranial EEG: Inclusion Criteria * Patients must be age 18 years or older. There is no upper age limit. * Patients must have a diagnosis of refractory epilepsy undergoing intracranial EEG recording for clinical purposes. Patients with Intracranial EEG: Exclusion Criteria * Patient has additional neurological condition (such as stroke or dementia) or a psychiatric condition (such as active psychosis or suicidal ideation) and are deemed inappropriate for the study * Patients are not able to provide informed consent for any reason (e.g. encephalopathic, experiencing a seizure) Patients with Scalp EEG: Inclusion Criteria * Patients must be age 18 years or older. There is no upper age limit. * Patients must have a probable diagnosis of epilepsy. Patients with Scalp EEG: Exclusion Criteria * Patient has additional neurological condition (such as stroke or dementia) or a psychiatric condition (such as active psychosis or suicidal ideation) and are deemed inappropriate for the study * Patients are not able to provide informed consent for any reason (e.g. encephalopathic, experiencing a seizure) Normal Controls: Inclusion Criteria * Participants must be age 18 years or older. There is no upper age limit. * Participants must be able to provide informed consent for themselves. Normal Controls: Exclusion Criteria • Determined not to be appropriate normal control for the study population
Contact & Investigator
Krzysztof A Bujarski, MD
PRINCIPAL INVESTIGATOR
Dartmouth-Hitchcock Medical Center
Frequently Asked Questions
Who can join the NCT05529264 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05529264 currently recruiting?
Yes, NCT05529264 is actively recruiting participants. Contact the research team at krzysztof.a.bujarski@hitchcock.org for enrollment information.
Where is the NCT05529264 trial being conducted?
This trial is being conducted at Lebanon, United States.
Who is sponsoring the NCT05529264 clinical trial?
NCT05529264 is sponsored by Dartmouth-Hitchcock Medical Center. The principal investigator is Krzysztof A Bujarski, MD at Dartmouth-Hitchcock Medical Center. The trial plans to enroll 175 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.